5EA Stock Chart & Stats
€20.69
€0.00(0.00%)
At close: 4:00 PM EDT
€20.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€14.74 - €23.15
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
€10.76B
Enterprise Value€15.84K
Total Cash (Recent Filing)€530.00M
Total Debt (Recent Filing)€3.92B
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 10, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding499,621,830
10 Day Avg. Volume11
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.86Price Target Upside29.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.97
Revenue Forecast (FY)€4.40B
Bulls Say, Bears Say
Bulls Say
Raised Guidance & Revenue MomentumManagement’s raised revenue outlook and Q2 organic growth demonstrate durable demand across pet and farm end markets. A multi-percent organic growth baseline supports reinvestment, production scaling and margin leverage over the next 2–6 months as new launches ramp and distribution expands.
Strong Innovation & Product TractionHigh clinic penetration, reorder rates and accelerating product share signal durable adoption of new therapeutics. Sustained uptake of Zenrelia and Credelio Quattro should drive recurring revenue, mix improvement and pricing power, supporting long‑term top‑line resilience and gross‑margin expansion.
Positive Cash Generation & DeleveragingConsistent positive operating cash flow and free cash flow, alongside falling net debt and a year‑end net leverage target near 3.0x, provide durable financial flexibility. This cash profile funds launches and R&D while reducing refinancing risk and supporting margin improvement initiatives.
Bears Say
Negative Net Margin & ROEDespite EBITDA improvement, persistent negative net margins and a negative ROE indicate the company has not yet converted operational gains into shareholder returns. This constrains capacity to fund growth internally and elevates sensitivity to cost or revenue setbacks over the medium term.
Supply Constraint On BefrenaA supply bottleneck for a high‑demand monoclonal antibody delays full commercial scale and revenue capture. Protracted production ramp risks lost share, slower innovation revenue growth and delayed margin benefits from the launch, affecting durable growth assumptions into 2027.
Elevated OpEx & Inflationary PressuresSustained higher operating spending for DTC, launches and R&D, plus inventory cost and inflationary headwinds, raise the structural expense baseline. If these pressures persist, they could compress margins and delay consistent net profitability despite top‑line gains.
5EA FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was €14.74 and its highest was €23.15 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is €10.76B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 05, 2026. The company reported €0.292 earnings per share for the quarter, beating the consensus estimate of €0.231 by €0.061.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.18.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,621,830 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of €0.292 in its last earnings report, beating expectations of €0.231. Following the earnings report the stock price went down -0.498%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in DE:5EA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€26.86 (29.84% Upside)
€26.86 (29.84% Upside)
Blogger Sentiment
Neutral
DE:5EA Sentiment 60%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $537.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
5EA Company Deck
5EA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.View all DE:5EA earnings summaries5EA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€26.86
▲(29.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









